{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:59Z","timestamp":1753891799797,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Light chain amyloidosis (AL) with cardiac involvement is associated with poor prognosis. The existing prognostic assessment system does not consider treatment-related factors, and there is currently no effective system for predicting the response. The purpose of this study was to build an individualized, dynamic assessment model for cardiac response and overall survival (OS) for AL patients with cardiac involvement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The records of 737 AL patients with cardiac involvement were collected through cooperation with 18 hospitals in the Chinese Registration Network for Light-chain Amyloidosis (CRENLA). We used univariate and multivariate analyses to evaluate the prognostic factors for OS and cardiac response. Then, two nomogram models were developed to predict OS and cardiac response in AL patients with cardiac involvement.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A nomogram including four independent factors from the multivariate Cox proportional hazards analysis\u2014Mayo staging, courses of treatment, hematologic response, and cardiac response\u2014was constructed to calculate the possibility of achieving survival by adding all the points associated with four variables. The higher the score, the more likely death would occur. The other nomogram model included the courses of treatment, hematological response, and different treatment regimens, and was correlated with cardiac response. The higher the score, the more likely a cardiac response would occur.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, based on the large Chinese cohort of patients with AL and cardiac involvement, we identified nomogram models to predict cardiac response and OS. These models are more individualized and dynamic, and therefore, they have important clinical application value.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.758502","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T11:51:42Z","timestamp":1639050702000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Nomogram Model for Dynamic and Individual Prediction of Cardiac Response and Survival for Light Chain Amyloidosis in 737 Patients With Cardiac Involvement"],"prefix":"10.3389","volume":"11","author":[{"given":"Yang","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanze","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy291","article-title":"AL Amyloidosis: Advances in Diagnostics and Treatment","volume":"34","author":"Rysava","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e2018022","DOI":"10.4084\/MJHID.2018.022","article-title":"Light Chain Amyloidosis","volume":"10","author":"Milani","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11912-017-0607-4","article-title":"Cardiac Amyloidosis: Diagnosis and Treatment Strategies","volume":"19","author":"Tuzovic","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu Rev Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11912-021-01028-8","article-title":"Updates in Cardiac Amyloidosis Diagnosis and Treatment","volume":"23","author":"Stern","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2018.03.017","article-title":"Nomograms Are Key Decision-Making Tools in Prostate Cancer Radiation Therapy","volume":"36","author":"Caulfield","year":"2018","journal-title":"Urol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-020-06358-0","article-title":"Prognostic Nomograms Based on Immune Scores for Head-Neck Squamous Cell Carcinoma Patients","volume":"278","author":"Li","year":"2021","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.03.018","article-title":"Prognostic and Predictive Factors in Patients With Brain Metastases From Solid Tumors: A Review of Published Nomograms","volume":"126","author":"Nieder","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.100","article-title":"Consensus Guidelines for the Conduct and Reporting of Clinical Trials in Systemic Light-Chain Amyloidosis","volume":"26","author":"Comenzo","year":"2012","journal-title":"Leukemia"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71116-7","article-title":"Nomograms in Oncology: More Than Meets the Eye","volume":"16","author":"Balachandran","year":"2015","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5652935","article-title":"Prognostic Nomogram for the Overall Survival of Patients With Newly Diagnosed Multiple Myeloma","volume":"2019","author":"Zhang","year":"2019","journal-title":"BioMed Res Int"},{"key":"B16","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/bjh.13155","article-title":"Guidelines on the Management of AL Amyloidosis","volume":"168","author":"Wechalekar","year":"2015","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European Collaborative Study of Cyclophosphamide, Bortezomib, and Dexamethasone in Upfront Treatment of Systemic AL Amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084574","article-title":"Lenalidomide, Melphalan and Dexamethasone in a Population of Patients With Immunoglobulin Light Chain Amyloidosis With High Rates of Advanced Cardiac Involvement","volume":"98","author":"Dinner","year":"2013","journal-title":"Haematologica"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21822","article-title":"Discordance Between Serum Cardiac Biomarker and Immunoglobulin-Free Light-Chain Response in Patients With Immunoglobulin Light-Chain Amyloidosis Treated With Immune Modulatory Drugs","volume":"85","author":"Dispenzieri","year":"2010","journal-title":"Am J Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-305136","article-title":"Increases in B-Type Natriuretic Peptide (BNP) During Treatment With Lenalidomide in AL Amyloidosis","volume":"116","author":"Tapan","year":"2010","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0600-y","article-title":"Treatment of Patients With Advanced Cardiac AL Amyloidosis With Oral Melphalan, Dexamethasone, and Thalidomide","volume":"88","author":"Palladini","year":"2009","journal-title":"Ann Hematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-722496","article-title":"First Report of Safety and Efficacy of Daratumumab in 2 Cases of Advanced Immunoglobulin Light Chain Amyloidosis","volume":"128","author":"Sher","year":"2016","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0262-2","article-title":"Daratumumab-Based Therapy in Patients With Heavily-Pretreated AL Amyloidosis","volume":"33","author":"Abeykoon","year":"2019","journal-title":"Leukemia"},{"key":"B24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.758502\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T11:51:45Z","timestamp":1639050705000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.758502\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,9]]},"references-count":25,"alternative-id":["10.3389\/fonc.2021.758502"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.758502","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,12,9]]},"article-number":"758502"}}